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Abstract
CD8 T cells play a critical role in control of chronic viral infections; however, the role of these cells in containing persistent
bacterial infections, such as those caused by Mycobacterium tuberculosis (Mtb), is less clear. We assessed the phenotype and
functional capacity of CD8 T cells specific for the immunodominant Mtb antigens CFP-10 and ESAT-6, in patients with
pulmonary tuberculosis (TB) disease, before and after treatment, and in healthy persons with latent Mtb infection (LTBI). In
patients with TB disease, CFP-10/ESAT-6-specific IFN-c+ CD8 T cells had an activated, pro-apoptotic phenotype, with lower
Bcl-2 and CD127 expression, and higher Ki67, CD57, and CD95 expression, than in LTBI. When CFP-10/ESAT-6-specific IFN-c+
CD8 T cells were detectable, expression of distinct combinations of these markers was highly sensitive and specific for
differentiating TB disease from LTBI. Successful treatment of disease resulted in changes of these markers, but not in
restoration of CFP-10/ESAT-6-specific CD8 or CD4 memory T cell proliferative capacity. These data suggest that high
mycobacterial load in active TB disease is associated with activated, short-lived CFP-10/ESAT-6-specific CD8 T cells with
impaired functional capacity that is not restored following treatment. By contrast, LTBI is associated with preservation of
long-lived CFP-10/ESAT-6-specific memory CD8 T cells that maintain high Bcl-2 expression and which may readily
proliferate.
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Introduction
The vast majority of individuals infected with Mycobacterium
tuberculosis (Mtb) never develop clinical symptoms of tuberculosis
(TB) disease [1], thus providing compelling evidence of the ability
of the host immune response to successfully control the pathogen.
However, host mechanisms of protection against development of
TB disease have not been fully elucidated.
A clear role for CD4 T cells in immunological control of Mtb
infection has been demonstrated in mouse models: increased
susceptibility to Mtb infection was shown in MHC class II-/- mice
[2], and rapid reactivation of Mtb replication and decreased
survival followed experimental antibody-mediated depletion of
CD4 T cells [3-5]. However, a direct role for Mtb-specific CD8 T
cells in mediating protective immunity to Mtb is less clear. Similar
to CD4 T cells, CD8 T cells can produce IFN-c and TNF-a,
which directly activate macrophages and promote the production
of nitrogen and oxygen radicals to suppress Mtb growth [6-8].
CD8 T cells can kill Mtb-infected cells by production of cytotoxic
molecules such as perforin and granulysin, and/or may modulate
the microenvironment by production of cytokines [9-11]. CD8 T
cells have been shown to mediate suppression of Mtb growth in
vitro in blood-derived macrophages [12] as well as autologous
alveolar macrophages [13]. Mtb infection of CD8 T cell-deficient
mice, or depletion of CD8 T cells in vivo following infection, has
been reported to result in higher bacterial burdens [14-16].
However, other similar murine studies have reported no differ-
ences in bacterial load or survival in the absence of CD8 T cells
[4,5,17]. In rhesus macaques, depletion of CD8 T cells results in
loss of Bacille Calmette Gue´rin (BCG) vaccine-induced immunity
and reduced immunity to Mtb [18].
MHC class I-restricted CD8 T cells recognizing a variety of
Mtb antigens have been detected in individuals with latent Mtb
infection (LTBI) and with active TB disease [19-29]. IFN-c-
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producing CD8 T cells specific for epitopes within the immuno-
dominant antigens CFP-10 and ESAT-6 have been more readily
detectable in peripheral blood of patients with active TB disease,
compared with individuals with LTBI [30-32]. Despite higher
frequencies of cytokine-producing Mtb-specific CD8 T cells in
peripheral blood of patients with TB, other functions of Mtb-
specific CD8 T cells, including cytolytic activity [33], production
of cytotoxic molecules [34], and proliferation [30,32,35], have
been reported to be impaired in patients with active TB.
Immunoregulatory molecules that have been associated with
CD8 T cell dysfunction and immune exhaustion in chronic viral
infections, including CD160, programmed death receptor 1 (PD-
1), and 2B4 [36], have been reported to be expressed at low levels
on CFP-10 and ESAT-6-specific CD8 T cells, both in the setting
of latent infection and active TB disease [32]. Moreover,
expression of the immunoregulatory molecule TIM-3, which has
also been associated with T cell dysfunction in chronic viral
infections [37], has been reported to be associated with high
effector function capacity when expressed by Mtb-specific CD4
and CD8 T cells [38]. Thus phenotypic molecules that are
associated with functional impairment of antigen-specific CD8 T
cells in the setting of active TB disease in humans have not been
well defined.
Progressive dysfunction of antigen-specific CD8 T cells has been
described in the context of chronic viral infections [36,39–42].
This dysfunction correlates with antigen load and has been
associated with distinct phenotypic profiles of antigen-specific T
cells, such as loss of expression of CD127, the IL-7 receptor a
chain [43–45], and increased expression of inhibitory receptors
[46,47]. Antigen-specific CD8 T cells in chronic infection also
express low levels of the anti-apoptotic molecule Bcl-2 [48–50] and
high levels of pro-apoptotic CD95 (Fas), rendering these cells more
susceptible to apoptosis and deletion [51–53]. Upregulation of
CD57 expression by CD8 T cells in chronic infections has been
linked to replicative senescence and greater propensity to antigen-
induced apoptosis [54–56].
The relationship between mycobacterial antigen load and the
phenotypic profiles of CFP-10/ESAT-6-specific CD8 T cells in
humans has not been well described. We hypothesized that
functional impairment of CFP-10/ESAT-6-specific CD8 T cells in
patients with active TB disease and high mycobacterial load would
be associated with dysregulated expression of phenotypic mole-
cules associated with memory, activation, senescence, and
apoptosis. We therefore examined the phenotypic profiles and
proliferative capacities of CFP-10/ESAT-6-specific CD8 T cells in
healthy asymptomatic individuals with LTBI and in patients with
active pulmonary TB disease, before and after successful
completion of anti-TB treatment.
Materials and Methods
Ethics Statement
All participants provided written informed consent to partici-
pate in the study, which was approved by the Human Research
Ethics Committee of the University of Cape Town, and by the
Western Cape Department of Health.
Study population and sample collection
HIV-uninfected persons between 18–65 years of age with latent
Mtb infection (LTBI) or with pulmonary tuberculosis disease (TB)
were recruited from the Cape Town region of South Africa.
Persons with LTBI were identified as healthy, asymptomatic
individuals (defined as individuals with negative symptom screen-
ing for all of the following TB-associated symptoms: persistent
cough, fever, night sweats, weight loss, or hemoptysis), with IFN-c+
CD4 or CD8 T cells to CFP-10 and/or ESAT-6 peptide pools in a
whole blood intracelluar cytokine staining assay [30], and with no
previous history of TB diagnosis or treatment. All patients with
pulmonary TB disease had either a positive sputum smear
microscopy, a positive sputum culture for Mtb, or both. In those
with TB disease, peripheral blood was collected between 0 and 7
days of starting standard drug treatment, which consisted of 2
months of isoniazid, rifampicin, pyrazinamide, and ethambutol,
followed by 4 months of isoniazid and rifampicin. TB treatment
was provided according to South African national health
guidelines, which include provisions for directly observed treat-
ment (DOT) for monitoring of adherence. Drug suscepbility
testing was conducted in accordance with the South African
National Tuberculosis Control Programme guidelines; all patients
tested for drug susceptibility were sensitive to first line TB drugs.
Some patients with TB disease were followed longitudinally, with
additional blood samples obtained at 2, 6, and 12 months after
starting treatment. All TB patients followed longitudinally on
treatment had an excellent response to treatment, as indicated by
resolution of symptoms and two negative sputum smears, taken on
two separate occasions, by the end of the 6 month treatment
period.
Antigens
15-mer peptides overlapping by 10 amino acids were synthe-
sized to correspond with the sequence of ESAT-6 and CFP-10. A
pool of overlapping peptides spanning the pp65 protein of human
cytomegalovirus (HCMV) was included in the intracellular
cytokine staining phenotyping assays (see below) for analysis of T
cell phenotypes specific for a chronic antigen other than Mtb. The
HCMV pp65 Peptide Set was obtained through the NIH AIDS
Reagent Program, Division of AIDS, NIAID, NIH. Peptide pools
for each of these were used at a concentration of 1.25 mg/ml/
peptide in PBMC ICS assays (see below), and at 0.1 mg/ml/
peptide in proliferation assays (see below). Staphylococcal entero-
toxin B (SEB; Sigma-Aldrich) was used at 1 mg/ml in the ICS
assays, and at 0.1 mg/ml in proliferation assays.
Intracellular cytokine staining (ICS) phenotyping assay
Cryopreserved PBMCs were thawed in medium containing
deoxyribonuclease I (DNAse; 100 mg/ml; Sigma-Aldrich), washed,
and rested for at least 6 hours at 37uC. Peptide pools were then
added for a total of 7 hours, with Brefeldin A (10 mg/ml) added
after the first 2 hours. Cells were stimulated with SEB or
incubated with no antigen, as positive and negative controls,
respectively. Cells were then washed in PBS and stained with
Vivid, fixed with FACS Lysing Solution, and permeabilized with
Perm/Wash Buffer (BD Biosciences). Cells were stained with
following mAbs: anti-CD3 allophycocyanin-H7 (SK7), anti-IFN-c
Alexa Fluor 700 (B27), anti-Ki67 PE (B56), anti-CD127 PerCP-
Cy5.5 (HIL-7R-M21), all from BD Biosciences, anti-CD8
QDot605 (3B5) from Life Technologies, anti-CD57 APC (NK-
1), and anti-CD95 PE-Cy7 (DX2), both from BioLegend. After
1 hour, cells were washed in Perm/Wash Buffer and acquired on a
BD LSRII flow cytometer.
PBMC proliferation assay
A six-day proliferation assay was performed as previously
described [30]. Briefly, freshly isolated peripheral blood mononu-
clear cells (PBMCs) were labeled with CellTrace Oregon Green
488 carboxylic acid diacetate, succinimidyl ester (OG; Life
Technologies). OG-labeled cells were incubated for 6 days with
either Mtb peptide pools, or the positive control SEB, or no
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antigen (negative control). Cells were then stained with LIVE/
DEAD Fixable Violet Dead Cell Stain (Vivid; Life Technologies),
fixed with FACS Lysing Solution (BD Biosciences), and stained
with anti-CD4 Qdot605 (S3.5, Life Technologies), anti-CD3
allophycocyanin-H7 (SK7), and anti-CD8 PerCP-Cy5.5 (SK-1),
both from BD Biosciences.
Flow cytometry
All flow cytometry data were acquired using a BD LSRII flow
cytometer with FACSDiva software (v6.0; BD Biosciences), and
analyzed using FlowJo (v9.5.2; TreeStar). Lymphocytes were gated
by morphological parameters (forward scatter and side scatter). T
cells were identified as CD3+ lymphocytes; live cells were identified
as Vividlo cells; proliferating cells were identified as OGlo cells. In
ICS phenotyping assays, CFP-10/ESAT-6-specific CD8 T cells
were defined as VividluCD3+CD8+IFN-c+ T cells following
stimulation with CFP-10 or ESAT-6 peptide pools. As confirmed
in a separate PBMC ICS assay, .90% of CD3+CD82IFN-c+ T
cells following stimulation with CFP-10 or ESAT-6 peptide pools
were found to be CD4+ (Fig. S3), and are thus referred to as CFP-
10/ESAT-6-specific CD4 T cells. Co-expression patterns of
phenotypic markers were analyzed using Pestle v1.7 (Mario
Roederer, Vaccine Research Center, National Institute of Allergy
and Infectious Diseases, National Institutes of Health) and Spice
v5.22 [57].
Data analysis
Responses in the ICS and proliferation assays were considered
positive if the frequency of cytokine-producing or proliferating T
cells in the stimulated sample was greater than the median plus 3
times the median absolute deviation of the negative control
samples. In addition, a minimum of 20 IFN-c+ T cell events above
background cytokine production was required for subsequent
phenotypic analysis in the ICS assay. Statistical analyses were
performed using Prism v6.0c (GraphPad Software, Inc.). Differ-
ences between groups were assessed using the Mann-Whitney U
test. The Wilcoxon matched pairs test was used to assess
differences in CFP-10/ESAT-6-specific T cell responses within
the same donor at different time points. To evaluate the predictive
value of CFP-10/ESAT-6-specific CD8 T cell phenotypic profiles,
a receiver operator characteristic (ROC) curve was generated and
logistic regression analysis performed. The predictive value of each
phenotypic pattern was evaluated by analysis of the area under the
curve (AUC). P values in phenotypic analyses were corrected for
multiple comparisons using Bonferroni correction to control the
family-wise error rate. For comparison of three or more groups, a
non-parametric Kruskal-Wallis test was performed, followed by
the Dunn’s post-test to account for multiple comparisons.
Results
Participants
Two groups of adults from the Cape Town region of South
Africa were recruited for this study: healthy, asymptomatic adults
with LTBI, and patients with active pulmonary TB disease. All
participants were seronegative for HIV-1 antibodies. Character-
istics of the study participants are summarized in Table 1.
CFP-10/ESAT-6-specific CD8 T cells have a short-lived,
pro-apoptotic phenotype in TB disease patients,
compared with persons with LTBI
Previous studies of chronic viral infections have clearly
demonstrated dysfunction of virus-specific CD8 T cells in the
context of persistent antigen stimulation, as well as distinct
phenotypic profiles when chronic and acute infections were
compared [36]. We have previously found differential functional
capacities of peripheral blood CFP-10/ESAT-6-specific CD8 T
cells in humans: those with active disease were more likely to have
cells producing cytokines ex vivo, whereas those with LTBI
characterstically had cells with robust proliferative capacity [30].
We hypothesized that the differential functional capacites of
CFP-10/ESAT-6-specific CD8 T cells observed in individuals
with LTBI and patients with TB disease would associate with
expression of cellular markers of activation, senescence, and
susceptibility to apoptosis. Thus, we measured expression of Ki67,
Bcl-2, CD127, CD57, and CD95 among CFP-10/ESAT-6-
specific CD8 T cells, identified by intracellular IFN-c expression
after short-term stimultion of PBMCs with CFP-10 and ESAT-6
peptide pools (Figure 1 and Figure S1). Of 38 individuals analyzed
in our ICS phenotyping assay (n = 18 LTBI and n=20 TB
disesase), 6 persons with LTBI (33%) and 13 patients with TB
disease (65%) had positive CFP-10 or ESAT-6-specific CD8 T cell
responses that were subjected to further phenotypic analyses
(Figure 1A, B). Compared with persons with LTBI, CFP-10/
ESAT-6-specific CD8 T cells from TB diseased patients had
significantly higher expression of Ki67, CD57, and CD95, and
lower expression of the anti-apoptotic molecule Bcl-2 and memory
T cell marker CD127 (Figure 1C).
We next directly compared expression of these molecules
between the antigen-specific and total CD8 T cell populations
within the same individual. Compared with total CD8 T cells,
Ki67 expression was upregulated and Bcl-2 expression was
downregulated by CFP-10/ESAT-6-specific CD8 T cells from
patients with TB disease. By contrast, in individuals with LTBI,
expression of Ki67 and Bcl-2 was similar between CFP-10/ESAT-
6-specific CD8 T cells and the total CD8 T cell population
(Figure 1D). Together these data indicate that modulation of
expression of Ki67 and Bcl-2 within CFP-10/ESAT-6-specific
CD8 T cells is unique to patients with active disease, and provide
further evidence of an activated, pro-apoptotic population of CFP-
10/ESAT-6-specific CD8 T cells in the context of high bacterial
load.
Co-expression patterns of Bcl-2, CD57, and CD95 by CFP-
10/ESAT-6-specific CD8 T cells distinguish individuals
with LTBI and patients with TB disease
We next used Boolean analysis to analyze co-expression patterns
of Bcl-2, Ki67, CD127, CD57, and CD95 to determine if
phenotypically distinct populations of CFP-10/ESAT-6-specific
CD8 T cells differed significantly between individuals with LTBI
and active disease. A combination of Bcl-2, CD57, and CD95
expression allowed differentiation of individuals with LTBI from
patients with TB disease (Figure 2A and data not shown). The
majority of CFP-10/ESAT-6-specific CD8 T cells in persons with
LTBI co-expressed Bcl-2 and CD95, in the absence of CD57; by
contrast, the majority of CFP-10/ESAT-6-specific CD8 T cells in
patients with TB disease expressed CD95, with or without CD57
co-expression, but lacked Bcl-2 expression (Figure 2A). Cells
expressing Ki67, a nuclear protein indicative of cell turnover in
vivo, were found almost exclusively within the Bcl-
22CD572CD95+ subset (data not shown). The proportion of
CFP-10/ESAT-6-specific CD8 T cells displaying a Bcl-
2+CD572CD95+ phenotype demonstrated the greatest power to
distinguish LTBI from TB disease (Figure 2B), with 100%
sensitivity and specificity (Figure 2C). In addition, the proportion
of Bcl-22CD57+CD95+ and of Bcl-2+CD572CD952 CFP-10/
Human CD8 T Cell Phenotype in TB
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ESAT-6-specific CD8 T cells classified individuals with LTBI and
TB disease with .90% sensitivity and specificity (Figure S2).
Pro-apoptotic phenotype of CFP-10/ESAT-6-specific CD4
T cells in patients with TB disease
Although distinct patterns of Bcl-2, CD57, and CD95 co-
expression by CFP-10/ESAT-6-specific CD8 T cells were highly
sensitive and specific in distinguishing latent infection from active
disease, these phenotypic measurements can only be analyzed in
individuals who have sufficient numbers of specific CD8 T cells to
be detectable in blood ex vivo. CFP-10/ESAT-6-specific CD8 T
cells are generally less readily detectable in peripheral blood than
CFP-10/ESAT-6-specific CD4 T cells, particularly in the setting
of LTBI [30]. Therefore, we analyzed expression of each
phenotypic marker on CFP-10/ESAT-6-specific
CD3+CD82IFN-c+ cells, .90% of which were confirmed to be
CD4+ in a separate ICS assay (Figure S3), and thus referred to
here subsequently as CD4 T cells. Similar to CD8 T cells, CFP-
10/ESAT-6-specific CD4 T cells expressed significantly higher
levels of Ki67 and CD95, and lower levels of Bcl-2, in patients with
TB disease, compared with individuals with LTBI (Figure 3A).
However, unlike CFP-10/ESAT-6-specific CD8 T cells, expres-
sion of CD127 and CD57 by CFP-10/ESAT-6-specific CD4 T
cells was not different between individuals with LTBI and patients
with active TB disease (Figure 3A). Boolean analysis of Bcl-2, Ki67
and CD95 co-expression by CFP-10/ESAT-6-specific CD4 T cells
indicated that Bcl-22CD95+Ki67+ CD4 T cells were found almost
exclusively in patients TB patients, and rarely in individuals with
LTBI (Figure 3B-C; Figure S4). TB patients also expressed higher
proportions of CFP-10/ESAT-6-specific CD4 T cells with a Bcl-
22CD95+Ki672 phenotype, whereas individuals with LTBI had
greater proportions of Bcl-2+ cells, with or without CD95 co-
expression, in the absence of Ki67 (Figure 3C-E; Figure S4). No
differences in expression of these molecules were found on
cytomegalovirus (CMV) pp65-specific CD4 T cells within the
same individuals (Figure 3F), thus suggesting the phenotypically
distinct subsets of antigen-specific CD4 T cells expressing these
combinations of Bcl-2, Ki67, and CD95 are unique to CFP-10/
ESAT-6-specific CD4 T cells in TB patients, and not indicative of
generalized immune activation and inflammation in the setting of
active disease.
CFP-10/ESAT-6-specific CD8 T cell phenotype is
associated with mycobacterial antigen load
Co-expression patterns of Bcl-2, CD57 and CD95 by CFP-10/
ESAT-6-specific CD8 T cells were significantly different between
individuals with LTBI and patients with active TB at the time of
diagnosis. We next performed a longitudinal analysis of CFP-10/
ESAT-6-specific CD8 T cell phenotype in patients with active TB
during the treatment period to further define the relationship
between CFP-10/ESAT-6-specific CD8 T cell phenotype and
mycobacterial antigen load (Figure 4A-B). By the end of the 6-
month TB treatment period, Ki67 and CD95 expression had
decreased, whereas Bcl-2 and CD127 expression increased in
CFP-10/ESAT-6-specific CD8 T cells, compared with pre-
treatment levels (Figure 4C). As all patients had an excellent
clinical response to therapy, these data therefore suggest that
mycobacterial load drives distinct changes in CFP-10/ESAT-6-
specific CD8 T cell phenotype.
To address the kinetics of mycobacterial antigen load-associated
changes in CFP-10 and ESAT-6-specific CD8 T cell phenotype,
we compared expression of each molecule on CFP-10/ESAT-6-
specific CD8 T cells between persons with LTBI, who had not
received any treatment, and TB diseased patients at three time
points: pre-treatment, and 2 and 6 months following initiation of
treatment. After 2 months of treatment, expression of Ki67 and
CD95 by CFP-10/ESAT-6-specific CD8 T cells had decreased to
similar levels observed in persons with LTBI (Figure 4D–E). By
contrast, even after successful completion of the standard course of
6 months of anti-TB treatment, expression of Bcl-2 and CD127 by
CFP-10/ESAT-6-specific CD8 T cells of TB disease patients
remained significantly lower than in persons with LTBI
(Figure 4F–G).
Finally, we investigated whether the longitudinal phenotypic
changes in CFP-10 and ESAT-6-specific CD8 T cells were
associated with restoration of functional capacity. We therefore
measured CFP-10/ESAT-6-specific T cell proliferative capacity
(Figure 5A), a functional capacity that is significantly impaired in
patients with TB disease [30], in patients before, during, and after
treatment for TB disease. There was no evidence of sustained
augmentation of CFP-10/ESAT-6-specific CD8 T cell prolifera-
tive capacity after completion of treatment (Figure 5B). Moreover,
the proliferative capacity of patients with TB disease at all time
points analyzed remained significantly lower than in persons with
LTBI (Figure 5C). Similar results were found for CFP-10/ESAT-
6-specific CD4 T cells (Figure 5D–E), thus suggesting lack of
restoration of CD8 T cell proliferative capacity after TB treatment
may be associated with impaired CD4 T cell help in patients who
develop TB disease. Taken together, these data indicate the
phenotypic profile of CFP-10 and ESAT-6-specific CD8 T cells is
associated with mycobacterial antigen load; however, despite
successful treatment for active TB disease, CFP-10/ESAT-6-
specific CD8 T cell function, as measured by proliferative
capacity, is not restored.
Discussion
We characterized phenotypic profiles of human CFP-10 and
ESAT-6-specific CD8 T cells that are associated with immune
containment of the pathogen – LTBI – and with active pulmonary
Table 1. Characteristics of study population.
Participant Group n AFB Sputum Smear Positive, n (%) TB Tx, Days (Range)b Age, Years (Range)c Sex (% Male)
LTBI 42 N/A N/A 25 (18–50) 40%
TB 47 39 (83%)a 4 (0–7) 38 (20–65)d 70%d
aThe remaining 8 individuals with TB were sputum smear-negative, culture positive for M. tuberculosis.
bValues denote median number of days on anti-TB treatment at first sample collection (range).
cValues denote median (range).
dp,0.05, compared with LTBI.
N/A, not applicable.
doi:10.1371/journal.pone.0094949.t001
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disease. We made the following observations: 1) In TB diseased
persons, CFP-10/ESAT-6-specific CD8 T cells are characterized
by a pro-apoptotic phenotype and by increased expression of
molecules involved in activation, apoptosis, and senescence, when
compared with persons with LTBI; 2) When CFP-10/ESAT-6-
specific CD8 T cells are detectable, distinct phenotypic profiles of
Bcl-2, CD57, and/or CD95 co-expression are highly specific and
sensitive in differentiating TB disease and LTBI; 3) Similar to CD8
T cells, CFP-10/ESAT-6-specific CD4 T cells in patients with TB
disease also display a pro-apoptotic phenotype, with increased
Ki67 and CD95 expression and decreased Bcl-2 expression; 4)
CFP-10/ESAT-6-specific CD8 T cell phenotype is likely to be
Figure 1. CFP-10/ESAT-6-specific CD8 T cells in patients with TB have a short-lived, pro-apoptotic phenotype. PBMCs from individuals
with LTBI (n = 18) and patients with TB disease (n = 20) were stimulated for 6 hours with CFP-10 and ESAT-6 peptide pools; intracellular IFN-c
production was measured in CD8 T cells by flow cytometry. (A) Frequencies of CFP-10 and ESAT-6-specific IFN-c+ CD8 T cells in persons with LTBI and
patients with TB disease. Horizontal lines represent the median. Data are shown after subtraction of background cytokine production in the negative
control condition. The dotted line separates individuals who met the criteria for a positive CD8 T cell response for further phenotypic analyses (above
dotted line: n = 6 LTBI; n = 13 TB disease), and individuals in whom the frequency of IFN-c+ CD8 T cells was too low to meet the criteria for further
phenotypic analyses (below dotted line). (B) Representative flow cytometry data from an individual with LTBI and a patient with TB disease, following
stimulation of PBMCs with an ESAT-6 peptide pool. Grey cells indicate the total CD8 T cell population (gated on VIVIDluCD3+CD8+ cells); black cells
indicate ESAT-6-specific CD8 T cells (gated on VIVIDluCD3+CD8+IFN-c+ cells). (C) Summary data of the percentage of specific IFN-c+ CD8 T cells
expressing Ki67, Bcl-2, CD127, CD57 and CD95 in individuals with LTBI and TB disease. Differences were assessed using the Mann-Whitney test. 1
indicates p values that did not remain significant after applying the Bonferroni correction for multiple comparisons. (D) Comparison of the expression
of intracellular Ki67 and Bcl-2 between the total CD8 T cell population and specific IFN-c+ CD8 T cells within the same individual. Only individuals
meeting the criteria for a positive CD8 T cell response in the ICS assay were included in this paired analysis (n = 6 LTBI; n = 13 TB disease). Differences
were assessed using the Wilcoxon matched-pairs test.
doi:10.1371/journal.pone.0094949.g001
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associated with mycobacterial antigen load, as suggested by rapid
changes in expression of specific molecules following initiation of
treatment; 5) Despite distinct changes in CFP-10/ESAT-6-specific
CD8 T cell phenotype following successful treatment for TB
disease, expression of Bcl-2 and CD127 remains lower than levels
observed by CFP-10/ESAT-6-specific CD8 T cells in persons with
LTBI, thus suggesting greater susceptibility to apoptosis in treated
TB patients; neither does CFP-10/ESAT-6-specific CD8 nor CD4
T cell proliferative capacity recover following completion of TB
treatment.
Progressive dysfunction of antigen-specific CD8 T cells in
chronic viral infections has been well described [58]; however,
much less is known about potential CD8 T cell dysfunction in
chronic bacterial infections of humans. Inefficient control of Mtb
infection in both humans and animal models of infection may be
due to marked susceptibility of T cells to apoptosis [59–61]. This
was supported by our findings that CFP-10/ESAT-6-specific CD8
T cells from TB patients have reduced expression of Bcl-2, a
molecule which inhibits programmed cell death by binding to the
pro-apoptotic proteins Bax and Bak [62]. We also showed
upregulation of CD95 by CFP-10/ESAT-6-specific CD8 T cells
of patients with TB; susceptibility to apoptosis has previously been
linked to downregulation of Bcl-2 in conjunction with upregulation
of CD95 (Fas) [51–53,63]. Moreover, suboptimal immunity to
another intracellular human pathogen, Trypanosoma cruzi, has been
associated with generation of specific CD8 T cells that lack
proliferative capacity and simultaneously express high levels of
CD95 [64]. Thus, our data from TB diseased patients are
consistent with generation of suboptimal CD8 T cell immunity
and a pro-apoptotic T cell phenotype, similar to that previously
described in other chronic infections. Future studies utilizing
MHC class I tetramers will be necessary to determine whether
apoptosis is directly induced in CFP-10/ESAT-6-specific CD8 T
cells following stimulation with cognate antigen, or whether these
cells persist in a functionally inactive state.
Figure 2. Differential co-expression patterns of Bcl-2, CD57 and CD95 by CFP-10/ESAT-6-specific CD8 T cells distinguish individuals
with LTBI and patients with TB. Boolean analysis was performed to determine co-expression patterns of Bcl-2, CD57, and CD95 by CFP-10 and
ESAT-6-specific CD8 T cells detected by ICS, as described in Figure 1. (A) Co-expression patterns of Bcl-2, CD57, and CD95 by specific IFN-c+ CD8 T
cells detectable in individuals with LTBI (open bars; n = 6) and patients with TB disease (grey bars; n = 13). Cells were gated on VIVIDluCD3+CD8+IFN-c+
cells. Differences were assessed using the Mann-Whitney test. 1 indicates p values that did not retain statistical significance after applying the
Bonferroni correction for multiple comparisons. Pie graphs indicate the median proportion of each population contributing to the total specific IFN-
c+ CD8 T cell response. (B) Comparison of the proportion of Bcl-2+CD572CD95+ cells contributing to the total CFP-10 and ESAT-6-specific CD8 T cell
responses in individuals with LTBI and patients with TB disease. Horizontal lines represent the median. Differences were assessed using the Mann-
Whitney test. The dotted line indicates the cut-off (18.7%) that distinguishes individuals with LTBI and TB disease, with 100% specificity and 100%
sensitivity. (C) Receiver operator characteristic (ROC) curve indicating the sensitivity and specificity of the proportion of CFP-10/ESAT-6-specific CD8 T
cells that are Bcl-2+CD572CD95+ to distinguish individuals with LTBI and TB disease. An area under the ROC curve (AUC) analysis was performed to
further evaluate the performance of this phenotypic expression profile in distinguishing individuals with LTBI and TB disease.
doi:10.1371/journal.pone.0094949.g002
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Figure 3. Pro-apoptotic phenotype of CFP-10/ESAT-6-specific CD4 T cells in TB disease is characterized by increased expression of
Ki67 and CD95 and downregulation of Bcl-2. Expression of Ki67, Bcl-2, CD127, CD57, and CD95 by specific CD3+CD82IFN-c+ T cells was
measured by flow cytometry, as described in Figure 1. Greater than 90% of CD3+CD82IFN-c+ T cells following stimulation with CFP-10 and ESAT-6
peptide pools were found to be CD4+ (see Fig. S3), and are referred to here as CD4 T cells. Phenotypic analysis was performed on individuals with
positive CD4 T cell responses (defined as CD3+CD82IFN-c+) to either CFP-10 or ESAT-6 peptide pools (n = 16/18 with LTBI; n = 10/20 with TB disease).
(A) Summary data of the percentage of specific IFN-c+ CD4 T cells expressing Ki67, Bcl-2, CD127, CD57 and CD95 in individuals with LTBI and patients
with TB disease. Differences were assessed using the Mann-Whitney test, followed by the Bonferroni correction for multiple comparisons. (B) Flow
cytometry data indicating expression of Bcl-2 and Ki67 by ESAT-6-specific CD4 T cells in an individual with LTBI (top plot) and an individual with TB
disease (bottom plot). Plots are shown gated on CD3+CD82IFN-c+ T cells. (C) Co-expression patterns of Bcl-2, CD95, and Ki67 by IFN-c+ CD4 T cells in
individuals with LTBI (open bars; n = 16) and TB disease (grey bars; n = 10). Differences were assessed using the Mann-Whitney test, followed by the
Bonferroni correction for multiple comparisons. (D) Comparison of the proportion of Bcl-2+CD952Ki672 cells contributing to the total CFP-10/ESAT-6-
specific CD4 T cell responses in individuals with LTBI and patients with TB disease. Horizontal lines represent the median. Differences were assessed
using the Mann-Whitney test. The dotted line indicates the cut-off (7%) that distinguishes individuals with LTBI and TB disease, with 90% sensitivity
and 75% specificity. (E) Receiver operator characteristic (ROC) curve indicating the sensitivity and specificity of the proportion of CFP-10/ESAT-6-
specific CD4 T cells that are Bcl-2+CD952Ki672 to distinguish individuals with LTBI and TB disease. An area under the ROC curve (AUC) analysis was
performed to further evaluate the performance of this phenotypic expression profile in distinguishing individuals with LTBI and TB disease. (F) Co-
expression patterns of Bcl-2, CD95, and Ki67 by CMV pp65-specific CD4 T cells in individuals with LTBI (open bars) and TB disease (grey bars). Data are
shown from 16 individuals with LTBI and 13 patients with TB disease who had positive CD4 T cell responses to a CMV pp65 peptide pool. No
differences were found between individuals with LTBI and TB for any of the CMV-specific CD4 T cell subsets (Mann-Whitney test).
doi:10.1371/journal.pone.0094949.g003
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Our phenotypic analysis of CD8 T cells also revealed distinct
patterns of expression of phenotypic molecules in individuals with
LTBI and patients with TB disease: CFP-10/ESAT-6-specific
CD8 T cells in persons with LTBI co-expressed Bcl-2 and CD95
and did not express CD57, whereas patients with TB disease
expressed CD95, with or without CD57 co-expression, but
Figure 4. CFP-10/ESAT-6-specific CD8 T cell phenotype is associated with mycobacterial antigen load. Phenotypic analysis of CFP-10
and ESAT-6-specific IFN-c+ CD8 T cells was performed as described in Figure 1. Cells were analyzed prior to initiating anti-TB treatment (Pre-TB Tx),
and 2 months and 6 months after initiation of treatment. (A) Flow cytometry data indicating Ki67 and Bcl-2 expression by IFN-c+ ESAT-6-specific CD8
T cells from a TB diseased patient at two time points: prior to treatment and 6 months after initiation of treatment, corresponding to the end of the
treatment period. (B) Representative histogram overlays indicating expression of Bcl-2, CD127 and CD95 within CFP-10/ESAT-6-specific IFN-c+ CD8 T
cells. Black lines indicate expression prior to treatment; grey lines indicate expression 6 months after initiation of treatment. The numbers in the
upper right corner of the histograms indicate the median fluorescence intensity (MFI) at each time point (black: pre-treatment MFI; grey: 6-month TB
treatment MFI). Data shown in panels A and B are gated on VIVIDluCD3+CD8+IFN-c+ cells. (C) Summary data comparing the expression of Ki67, Bcl-2,
CD127 and CD95 on CFP-10/ESAT-6-specific IFN-c+ CD8 T cells from the same individual at two time points: prior to treatment (Pre-TB Tx) and at the
end of the 6-month treatment period (6 mo. TB Tx). Data are shown from 7 individuals who maintained positive CFP-10/ESAT-6-specific CD8 T cell
responses throughout the 6-month duration of treatment. Differences between time points were assessed using the Wilcoxon matched pairs test. 1
indicates p values that did not retain statistical significance after applying the Bonferroni correction for multiple comparisons. The proportion of CFP-
10/ESAT-6-specific IFN-c+ CD8 T cells that express Ki67 (D), CD95 (E), Bcl-2 (F), and CD127 (G) are shown for individuals with LTBI (n = 6), and TB
diseased patients prior to treatment (n = 13; Pre-TB Tx), and 2 months (n = 10; 2 mo. TB Tx) and 6 months (n = 8; 6 mo. TB Tx) following initiation of
treatment. Differences in panels D-G were first assessed using a Kruskal-Wallis test, followed by a Dunn’s post-test to correct for multiple
comparisons; 1 indicates p values that did not remain significant following correction with the Dunn’s post-test.
doi:10.1371/journal.pone.0094949.g004
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Figure 5. Lack of restoration of CFP-10/ESAT-6-specific CD4 and CD8 T cell proliferative capacity following completion of
treatment. The proliferative capacity of CFP-10/ESAT-6-specific CD4 and CD8 T cells was measured following a 6-day stimulation of freshly isolated
PBMCs with CFP-10 and ESAT-6 peptide pools. (A) Flow cytometry data of the proliferative capacity of antigen-specific CD8 T cells from a TB diseased
patient analyzed at 4 time points: prior to treatment (Pre-TB Tx), 2 months of treatment (2 mo. TB Tx), 6 months of treatment (6 mo. TB Tx,
corresponding to the end of the treatment period), and 6 months after completion of treatment (12 mo. TB Tx). The cells shown are gated on
VIVIDluCD3+CD8+ lymphocytes. The percentage on each plot indicates the percentage of proliferating CD8 T cells after subtraction of background
proliferation in the negative control condition. (B, D) Longitudinal analysis of the proliferative capacity of CFP-10 and ESAT-6-specific CD8 (panel B)
and CD4 (panel D) T cells in a subset of TB diseased patients who were followed for up to one year after TB diagnosis (n = 19 with at least 3 time
points available for analysis). There were no significant differences in the frequency of proliferating antigen-specific CD8 or CD4 T cells over time
(Kruskal-Wallis test). (C, E) Cross-sectional comparison of the CFP-10 and ESAT-6-specific CD8 (panel C) and CD4 (panel E) T cell proliferative capacity
between individuals with LTBI (n = 34) and active TB disease at 4 time points (pre-TB tx: n = 34; 2 months of TB tx: n = 19; 6 months of TB Tx
[corresponding to the end of the treatment period]: n = 25; 12 months post initiation of TB tx [corresponding to 6 months after the end of the
treatment period]: n = 10). Data are shown after subtraction of background proliferation in the negative control condition. Differences in panels C and
E were first assessed using a Kruskal-Wallis test, followed by a Dunn’s post-test to correct for multiple comparisons. All comparisons remained
significant following correction with the Dunn’s post-test.
doi:10.1371/journal.pone.0094949.g005
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expressed very low levels of Bcl-2. It is important to note that this
phenotypic signature is particular to CFP-10 and ESAT-6-specific
CD8 T cells, which were detectable ex vivo by our ICS assay in
33% of persons with LTBI and 65% of patients with TB disease.
However, we also observed significant differences in expression
patterns of Bcl-2, CD95, and Ki67 by CFP-10 and ESAT-6-
specific CD3+CD82IFN-c+ cells (confirmed in a separate ICS
assay to be CD4 T cells) in individuals with LTBI and patients
with TB disease, thus suggesting these phenotypic markers are also
differentially expressed by antigen-specific CD4 T cells in the
context of latent infection and active disease in humans. These
findings provide proof of concept that phenotypic signatures of
antigen-specific T cells may be further developed to correctly
classify individuals with different stages of Mtb infection and
disease with high degrees of sensitivity and specificity. It is
important to note in this study that we used IFN-c as a read-out of
antigen specificity, and thus the phenotype of antigen-specific T
cells that produce other effector molecules, in the absence of IFN-
c, remains unknown. Moreover, we focused on T cell responses
specific for epitopes in the immunodominant antigens CFP-10 and
ESAT-6, and it is possible that T cells specific for other antigens in
Mtb may display different phenotypic signatures than observed in
this study. Additional studies of larger cohorts of individuals are
required to further define antigen-specific T cell phenotypic
signatures that are associated with different Mtb infection and
disease states, and to assess the utility of Mtb-specific T cell
phenotypic signatures in predicting risk of TB disease prospec-
tively.
Within two months of treatment, CFP-10/ESAT-6-specific
CD8 T cell expression of Ki67 and CD95 in TB patients
decreased to similar levels observed in persons with LTBI,
suggesting that expression of particular markers by CFP-10/
ESAT-6-specific T cells may be an indication of bacterial load
levels. CFP-10/ESAT-6-specific CD8 T cell expression of Bcl-2
and CD127 also increased during treatment, but expression never
decreased to levels observed in persons with LTBI. It is important
to note here that individuals with positive tuberculin skin tests
(TST) and/or IFN-c release assays (IGRA) likely represent a
heterogeneous population encompassing a spectrum of bacterial
loads, ranging from eradication of bacteria to persistence of
bacteria replicating at low levels in the absence of clinical
symptoms [65,66]. The dynamic nature of LTBI is further
evidenced by imaging studies in Mtb-infected cynomolgous
macaques, which indicate high levels of variability of bacterial
replication and bacterial killing in individual granulomas within a
given host [67]. Thus the phenotype of CFP-10/ESAT-6-specific
CD8 T cells we observed in individuals with LTBI likely represents
a snapshot of antigen-specific CD8 T cell phenotypes, which may
change over time given the potential for fluctuations in the levels of
bacterial replication in individuals with persistent Mtb infection.
Given that expression of CD127, the IL-7 receptor a chain, is
important for T cell survival and homeostasis [68,69], and that
expression of Bcl-2 is important for preventing apoptosis [62], the
relatively lower levels of CD127 and Bcl-2 expression on CFP-10/
ESAT-6-specific CD8 T cells in patients treated for TB, compared
with individuals with LTBI, suggests antigen-specific memory
CD8 T cells may remain more prone to cell death in patients
following successful treatment of TB disease. Importantly, we also
found no evidence of restoration of CFP-10/ESAT-6-specific CD4
or CD8 T cell proliferative capacity, even in persons evaluated up
to 12 months after diagnosis and successful completion of
treatment. These data suggest memory CD4 and CD8 T cells
with impaired functional capacity persist in individuals successfully
treated for TB disease. It is tempting to speculate that
compromised memory T cell function is one mechanism
underlying the risk of recurrent TB disease, which can occur in
up to 20% of HIV-uninfected and one-third of HIV-infected
persons in South Africa [70].
In summary, our findings further define parameters of antigen-
specific CD8 T cells that are associated with successful immune
control of Mtb infection (LTBI) and development of active TB
disease. Moreover, the data presented here provide a platform for
future prospective, longitudinal studies to evaluate phenotypic and
functional signatures of CFP-10/ESAT-6-specific T cells that may
differentiate individuals at different stages of infection. Finally,
these data provide novel insights regarding immune parameters,
such as inadequate generation of long-term memory T cells and
lack of proliferative capacity, which may be associated with
susceptibility to recurrent episodes of active TB disease.
Supporting Information
Figure S1 Flow cytometry gating strategies used in
phenotypic analysis of CFP-10/ESAT-6-specific CD8 T
cells. PBMCs were thawed and stimulated with antigen as
described in Figure 1. (A) Doublet cell populations were excluded
using a forward scatter area (FSC-A) versus forward scatter height
(FSC-H) plot. Lymphocytes were selected based on FSC-A and
side scatter area (SSC-A) characteristics. Viable T cells were
defined as VIVIDluCD3+ cells. (B) CD8+ cells were further
selected within the viable T cell gate, and analyzed for expression
of IFN-c, CD57, Bcl-2, Ki67, CD95, and CD127. Representative
data from SEB-stimulated PBMCs from a patient with TB disease
are shown.
(PDF)
Figure S2 The proportion of CFP-10/ESAT-6-specific
CD8 T cells that are Bcl-22CD57+CD95+ and Bcl-
2+CD572CD952 differentiates individuals with LTBI
and TB disease. Co-expression patterns of Bcl-2, CD57, and
CD95 on CFP-10/ESAT-6-specific CD8 T cells were determined
as described in Figure 2. (A) Comparison of the proportion of Bcl-
22CD57+CD95+ cells contributing to the total CFP-10/ESAT-6-
specific CD8 T cell response in individuals with LTBI and patients
with TB disease. The dotted line indicates the cut-off (7%) that
distinguishes individuals with LTBI and patients with TB disease,
with 92% sensitivity and 100% specificity. An ROC curve is
shown indicating the sensitivity and specificity of the proportion of
CFP-10/ESAT-6-specific CD8 T cells that are Bcl-
22CD57+CD95+ in distinguishing individuals with LTBI and
patients with TB disease. (B) Comparison of the proportion of Bcl-
2+CD572CD952 cells contributing to the total CFP-10/ESAT-6-
specific CD8 T cell response in individuals with LTBI and patients
with TB disease. The dotted line indicates the cut-off (3.3%) that
distinguishes individuals with LTBI and patients with TB disease,
with 92% sensitivity and 100% specificity. An ROC curve is
shown indicating the sensitivity and specificity of the proportion of
CFP-10/ESAT-6-specific CD8 T cells that are Bcl-
2+CD572CD952 in distinguishing individuals with LTBI and
patients with TB disease. An area under the ROC curve (AUC)
analysis was performed to further evaluate the performance of
these particular phenotypic expression profiles in distinguishing
individuals with LTBI and patients with TB disease.
(PDF)
Figure S3 The majority of CFP-10 and ESAT-6-specific
CD3+CD82IFN-c+ T cells are CD4+. PBMCs from individuals
with LTBI and patients with TB disease were stimulated with
CFP-10 and ESAT-6 peptide pools for 6 hours as described in the
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Materials and Methods section. Cells were stained with LIVE/
DEAD Fixable Violet Dead Cell Stain (ViVid), anti-CD3
allophycocyanin-H7 (SK7), anti-IFN-c Alexa Fluor 700 (B27),
anti-CD8 PerCP-Cy5.5 (SK-1), all from BD Biosciences, and anti-
CD4 QDot605 (S3.5) from Life Technologies. (A) Flow cytometry
data representing the gating strategy for the analysis of CD4
expression on live CD3+CD82IFN-c+ T cells. Data are shown for
PBMCs stimulated with CFP-10 peptide pool from a patient with
TB disease (top row) and an individual with LTBI (bottom row).
(B) Composite data indicating the percentage of CD3+CD82IFN-
c+ T cells that are CD4+ in individuals with LTBI (n= 9) and
patients with TB disease (n = 5). Each data point represents a
single individual; colors indicate the antigen specificity of the
response measured. (C) Flow cytometry data indicating the gating
strategy used for phenotypic analysis of VIVIDluCD3+CD82IFN-
c+ cells. ESAT-6-specific IFN-c+ cells from an individual with
LTBI are shown as black dots overlayed on the total
VIVIDluCD3+CD82 population.
(PDF)
Figure S4 Predictive values of Bcl-2, CD95, and Ki67
expression by CFP-10/ESAT-6-specific CD4 T cells in
distinguishing individuals with LTBI from TB disease
patients. Co-expression patterns of Bcl-2, CD95, and Ki67 on
CFP-10/ESAT-6-specific CD4 T cells were determined as
described in Figure 3. (A) Comparison of the proportion of Bcl-
22CD95+Ki67+ cells contributing to the total CFP-10/ESAT-6-
specific CD4 T cell response in individuals with LTBI and TB
disease patients. The dotted line indicates the cut-off (7%) that
distinguishes individuals with LTBI and patients with TB disease,
with 80% sensitivity and 100% specificity. An ROC curve is
shown indicating the sensitivity and specificity of the proportion of
CFP-10/ESAT-6-specific CD4 T cells that are Bcl-
22CD95+Ki67+ in distinguishing individuals with LTBI and TB
disease patients. (B) Comparison of the proportion of Bcl-
2+CD95+Ki672 cells contributing to the total CFP-10/ESAT-6-
specific CD4 T cell response in individuals with LTBI and TB
disease patients. The dotted line indicates the cut-off (27%) that
distinguishes individuals with LTBI from TB disease patients, with
80% sensitivity and 81% specificity. An ROC curve is shown
indicating the sensitivity and specificity of the proportion of CFP-
10/ESAT-6-specific CD4 T cells that are Bcl-2+CD95+Ki672 in
distinguishing individuals with LTBI and TB disease patients. (C)
Comparison of the proportion of Bcl-22CD95+Ki672 cells
contributing to the total CFP-10/ESAT-6-specific CD4 T cell
response in individuals with LTBI and TB disease patients. The
dotted line indicates the cut-off (44%) that distinguishes individuals
with LTBI and patients with TB disease, with 80% sensitivity and
81% specificity. An ROC curve is shown indicating the sensitivity
and specificity of the proportion of CFP-10/ESAT-6-specific CD4
T cells that are Bcl-22CD95+Ki672 in distinguishing individuals
with LTBI and TB disease patients. For panels A, B, and C, an
area under the ROC curve (AUC) analysis was performed to
further evaluate the performance of these particular phenotypic
expression profiles in distinguishing individuals with LTBI from
TB disease patients.
(PDF)
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